A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder
Part of paid clinical trials in Bentonville, Arkansas.
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Study ID
- NCT04100096
- Phase
- PHASE2
- Status
- Completed
Conditions
- Borderline Personality Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Brexpiprazole — DRUGTablet
- Placebo — OTHERTablet
Study Details
There are currently no pharmacological treatments approved to treat borderline personality disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of brexpiprazole for the treatment of participants diagnosed with BPD to provide a pharmacological treatment for BPD.
Key Dates
- First listed
- Sep 24, 2019
- Start date
- Oct 17, 2019
- Status verified
- Jun 2024
- Primary completion
- Jun 27, 2021
- Completion
- Jun 27, 2021
Study Design
- Enrollment
- 332 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Brexpiprazole 2-3 Milligrams Per DayParticipants received brexpiprazole, 2-3 milligrams per day (mg/day) tablets, orally, up to Week 12 during the treatment phase.
- Placebo Comparator: PlaceboParticipants received brexpiprazole-matching placebo tablets, orally, up to Week 12 during the treatment phase.
Primary Outcome Measure
Change From Baseline in the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) Total Score [ Time Frame: Baseline (Day 0) to Week 10 ]
Locations (66)
Find similar trials in Bentonville, AR
Related Studies
- Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric PopulationsRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMSRecruiting · Stanford University · Stanford, California
- A Precision Medicine Approach to Target Engagement for Emotion RegulationRecruiting · Matthew Southward, PhD · Columbus, Ohio
- Neurostimulation Versus Therapy for Problems With EmotionsRecruiting · Duke University · Durham, North Carolina